Medical Research Council

Medical Research Council

Medical Research Council

Date Founded



1 Kemble Street,14th Floor,London, Greater London WC2B 4AN


Other Business & Consulting Services

Company Description

The Medical Research Council provides human healthcare and social services. It offers funding for biomedical spectrum, fundamental lab-based science, clinical trials and all major disease areas. The company was founded in 1913 and is headquartered in Swindon, the United Kingdom.

Executives & Employees

Chief Executive Officer & Director

Chief Operating & Finance Officer

Chief Strategy Officer

Director, Institute of Hearing Research

Director-Corporate Affairs

Director-External Affairs

Director-Major Projects

Director-Prion Unit

Clinical Professor-Immunopharmacology

Board of Directors

Director at Allied Domecq Plc

Chief Executive Officer & Director at Medical Research Council

Chairman at Mode Diagnostics Ltd.

Honorary Fellow at American Friends of London School of Hygiene & Tropical Medicine, Inc.

Chair, Immunology at Queen's University Belfast

Professor-Emeritus at University of Cambridge

Chief Executive Officer at Innovate UK

Director at Kardia Therapeutics, Inc.

Director at Medical Research Council

Distinguished Alumni
Gerard C. Grosveld is now Albert & Rosemary Joseph Endowed Chair in Genetic Research at St. Jude Children's Research Hospital, Inc.
Paths to Medical Research Council
Potential Connections via
Relationship Science
Medical Research Council
Recent Transactions
Details Hidden

inviCRO LLC purchases Imanova Ltd. from Medical Research Council, Imperial College London, University College London, King's College London

Advisors & Consultants
Legal Advisor

Managing Partner at Town Legal

Non-Profit Donations & Grants
Details Hidden

Senexis Ltd. is developing novel small molecule inhibitors of amyloid aggregation as potential therapeutic agents to inhibit and reverse the pathogenic process of protein misfolding, amyloid-related toxicity and inflammation. By screening focused libraries of drug-like inhibitors against multiple target amyloid-like proteins, Senexis has identified potent inhibitors that can selectively inhibit and reverse the formation of toxic ß-sheet-containing protein or peptide aggregates associated with specific amyloid-related diseases. Its optimized lead compounds for Alzheimer's disease have already shown pre-clinical efficacy in a variety of established models of memory and learning.It is Building a pipeline of drug development programs for neurological (Alzheimer's disease) and systemic degenerative conditions (type 2 diabetes, Dialysis Related Amyloidosis & Inclusion Body Myositis); and Developing the Company's composition-of-matter patent portfolio with a range of small molecule aggregation inhibitors, as well as inhibitors of amyloid-related inflammation for Alzheimer's disease.

Details Hidden

Imaxio SA develops biopharmaceutical products. It operates as a biotech company which focuses on vaccines, and based on the combination of commercial and research and development activities. The firm provides its services based on proprietary and Agilent DNA chips, notably CGH micro-array analyses. The company was founded by Christian Pradeyrol and Jean Chatellier in 2000 and is headquartered in Lyon, France.

Details Hidden

D-Gen Ltd. develops technologies for detection and prevention of prion diseases. The firm offers services that include prion reduction studies, in-process validation and contract sample testing. The company was founded in by John Collinge in May 2000 and is headquartered in London, the United Kingdom.